Following the results of FIGHT-202, the United States Food and Drug Administration (FDA) granted accelerated approval for pemigatinib in previously treated CCA patients harboring FGFR2 fusions or rearrangements [46]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.